Eli Lilly and Company $LLY Shares Bought by Oppenheimer & Co. Inc.

Key Points

• Oppenheimer increased its Eli Lilly stake by 10.5% in the third quarter, bringing its holdings to 86,953 shares valued at approximately $100.6 million. Institutional investors and hedge funds collectively own 82.53% of LLY.
• Eli Lilly’s investigational obesity drug retatrutide significantly outperformed Ozempic in a Phase 3 trial, strengthening the company’s competitive position, though the treatment is not yet approved.
• LLY shares opened at $1,289.36, near their 52-week high, while analysts maintain a “Moderate Buy” consensus and an average price target of $1,320.25. Key risks include upcoming earnings volatility, potential reductions in employer coverage for weight-loss drugs, and recent insider selling.

Oppenheimer & Co. Inc. grew its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 10.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 86,953 shares of the company's stock after buying an additional 8,271 shares during the quarter. Eli Lilly and Company makes up approximately 1.1% of Oppenheimer & Co. Inc.'s portfolio, making the stock its 12th largest position. Oppenheimer & Co. Inc.'s holdings in Eli Lilly and Company were worth $100,612,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Park Avenue Securities LLC grew its holdings in shares of Eli Lilly and Company by 4.7% during the third quarter. Park Avenue Securities LLC now owns 37,258 shares of the company's stock valued at $43,110,000 after buying an additional 1,656 shares in the last quarter. Segment Wealth Management LLC raised its position in Eli Lilly and Company by 0.6% during the third quarter. Segment Wealth Management LLC now owns 15,657 shares of the company's stock valued at $18,116,000 after buying an additional 93 shares during the period. Rainey & Randall Wealth Advisors Inc. lifted its stake in Eli Lilly and Company by 4.9% in the 3rd quarter. Rainey & Randall Wealth Advisors Inc. now owns 427 shares of the company's stock worth $494,000 after acquiring an additional 20 shares in the last quarter. Verdence Capital Advisors LLC lifted its stake in Eli Lilly and Company by 10.5% in the 3rd quarter. Verdence Capital Advisors LLC now owns 7,979 shares of the company's stock worth $9,233,000 after acquiring an additional 756 shares in the last quarter. Finally, Mill Capital Management LLC lifted its stake in Eli Lilly and Company by 0.3% in the 3rd quarter. Mill Capital Management LLC now owns 25,509 shares of the company's stock worth $29,516,000 after acquiring an additional 87 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CAO Donald Zakrowski sold 2,000 shares of the firm's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares of the company's stock, valued at approximately $14,131,250. The trade was a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is owned by corporate insiders.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide produced a major clinical win over Ozempic. In a Phase 3 head-to-head trial, the investigational drug delivered average weight loss of approximately 44–47 pounds, or 20%–21%, after 80 weeks, compared with about 21 pounds for Ozempic. Retatrutide also reduced A1C by 2.2% versus 1.8% for Ozempic 2 mg. The results strengthen Lilly’s long-term position in the highly competitive obesity-drug market, although retatrutide is not yet approved. Lilly retatrutide trial results
• Positive Sentiment: A federal judge rejected Novo Nordisk’s effort to block Lilly’s weight-loss drug advertising, finding insufficient evidence of meaningful sales harm. The ruling preserves Lilly’s ability to market Zepbound and its obesity portfolio using the challenged campaign. Court rejects Novo advertising challenge
• Positive Sentiment: Lilly is broadening its pipeline beyond GLP-1 medicines, with Kisunla in neuroscience and Taltz and newer therapies in immunology expected to support growth. The company also licensed the SpeechDx Alzheimer’s dataset to advance speech-based disease markers. Lilly neuroscience and immunology outlook
• Positive Sentiment: Bernstein raised its Lilly price target to $1,450 from $1,385, reflecting continued confidence in the company’s growth outlook. Lilly also declared a quarterly dividend of $1.73 per share.
• Neutral Sentiment: Patrik Jonsson will retire as head of Lilly International at year-end 2026, with Ilya Yuffa taking over the expanded Lilly Global Markets role on January 1, 2027. The transition is planned, but investors may monitor execution as the company consolidates its global commercial structure. Lilly leadership transition
• Negative Sentiment: Investors face substantial earnings-event risk ahead of Thursday’s report. Analysts expect roughly $6.67 in earnings per share and $22.62 billion in revenue, while options markets imply a potentially large post-earnings move. Reports that recent EPS estimates have fallen sharply add to caution.
• Negative Sentiment: About 16% of employers are reportedly considering reducing coverage for weight-loss medicines. Any broader reimbursement pullback could pressure demand for Zepbound and limit the market’s near-term growth assumptions. Employer weight-loss drug coverage concerns
• Negative Sentiment: Two Massachusetts hospitals joined a lawsuit alleging Lilly’s digital tools may put patient privacy at risk. The claims remain unresolved, but adverse findings could create legal, regulatory, and reputational costs. Patient privacy lawsuit

Eli Lilly and Company Trading Up 0.6%

NYSE:LLY opened at $1,289.36 on Thursday. The company has a market capitalization of $1.21 trillion, a P/E ratio of 43.27, a P/E/G ratio of 1.71 and a beta of 0.46. The stock's 50 day moving average price is $1,192.52 and its 200 day moving average price is $1,089.35. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a 52 week low of $809.63 and a 52 week high of $1,321.21.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to analysts' expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company's revenue was up 47.7% compared to the same quarter last year. During the same period in the previous year, the company earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts forecast that Eli Lilly and Company will post 33.22 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company's dividend payout ratio is 23.22%.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Truist Financial raised their price objective on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. BMO Capital Markets reiterated an "outperform" rating on shares of Eli Lilly and Company in a report on Thursday, October 1st. Weiss Ratings raised shares of Eli Lilly and Company from a "buy (b)" rating to a "buy (b+)" rating in a research report on Thursday, October 15th. The Goldman Sachs Group reissued a "buy" rating and issued a $1,413.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, October 20th. Finally, TD Cowen restated a "buy" rating and set a $1,250.00 price target on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,320.25.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.